Buyers maybe interested in the current change in politics and potential return to 'Obamacare', this potential could lead to gains in device utilisation as reported on Livewire Markets:
"The Patient Protection & Affordable Care Act 2010 (ObamaCare) has changed the economic landscape for US hospitals, redefining their structures towards quality metrics. Economic penalties now apply if hospitals do not comply with minimum overall quality. Dye volume is a key quality metric under ObamaCare – this may further incentivise hospitals to buy OSP’s device."
Also note snippet below of Osprey Medical presentation in 2016
A reinstated or renewed Patient Protection & Affordable Care Act under the Biden administration would no doubt place pressure on hospital administrators to deliver cost efficiencies on patients and government funds.....we know that DyeVert has these efficiencies by saving on contrast dye.
Note the Biden Administration will not have control of the senate so some work would be required for the scheme to be reinstated.
Either way still a large potential upside with or without Obama Care....the rest will follow and just need to start seeing the gap diminish between operation cost and sales derived income.
Keep well cheers Paul
OSP Price at posting:
2.1¢ Sentiment: Buy Disclosure: Held
